NEWTBVAC

2010 - 2014
12 million euro, funded by the European Commission under Framework Programme 7


TBVI is coordinator of NEWTBVAC, an impressive consortium of over 35 research institutions and a project focusing on the discovery and preclinical testing of new tuberculosis vaccine candidates.

With NEWTBVAC, TBVI wants to: 

  1. Sustain and innovate the current European pipeline with new vaccine discoveries, and advance the most promising candidates to clinical stages;

  2. Develop new, second generation vaccines. These vaccines should – either alone or in combination with existing vaccine candidates - be able to boost the current BCG vaccine (the only existing TB vaccine, which has little to no efficacy in preventing pulmonary TB) or replace BCG. Furthermore, the vaccines should also protect people with a latent or ‘sleeping’ TB infection from developing the infectious disease;

  3. Sustain and innovate the discovery, evaluation and testing of new biomarkers. These will be critically important for future monitoring of clinical trials, and reducing time and resources for clinical trials sites.

Over 35 universities, research institutes and industries from mostly Europe and Asia are collaborating in the project (see list of partners). The research will be supervised, evaluated and supported according to our working model.

NEWTBVAC is funded by the European Union under Framework Program 7, the European Union’s main instrument for funding research in Europe.

NEWTBVAC is the successor of the successful TBVAC project (2004-2009), which was coordinated by TBVI as well.

These are the results we reported so far to the European Commission:

Results in brief: NEWTBVAC supported 40 TB vaccine approaches during the past 4 years. 22 of them moved from research to discovery, 6 from discovery to preclinical phase and 4 went to phase 1 clinical trial. 17 biomarkers have been further characterized and validated and 18 new biomarkers were identified.
With these results NEWTBVAC enriched the global TB vaccine pipeline. Through their capacity to harness different immune mechanisms, the new generation candidates will develop into vaccines that may prevent latent TB infection, or even actively reduce subsequent reactivation, or re-emerging, of TB disease. Further development is needed and if the outcomes of the clinical trials are successful, the developed vaccines will save millions of lives and euros, reducing the economic health care burden. This would be a step forward in the right direction for the elimination of TB.

   

Contact

Danielle Roordink MSc
Project Manager
+31 320 277 554
danielle.roordink(at)tbvi.eu